Elucidation of involvement in tumorigenesis and clinical significance of CD25 expression in hematopoietic tumors

• Project/Area Number: 15K19556
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Hematology
• Research Institution: Jichi Medical University
• Principal Investigator: Fujiwara Shinichiro 自治医科大学, 医学部, 講師 (20438667)
• Research Collaborator: Muroi Kazuo 自治医科大学, 医学部, 教授 (50190939)
• Project Period (FY): 2015-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000); Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000); Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: CD25 / soluble IL-2 receptor / lymphoma / 可溶性IL-2レセプター / リンパ腫 / IL-2R / 濾胞性リンパ腫 / 急性骨髄性白血病

Outline of Final Research Achievements

CD25 positive acute myeloid leukemia (AML) was associated with poor prognosis after stem cell transplantation. CD25 expression was an independent risk factor for complete remission and event free survival in elderly AML. High level of pretreatment soluble CD25 was an independent prognostic factor for transformation in follicular lymphoma (FL). Measure of pretreatment and posttreatment soluble CD25 was useful to predict the prognosis of FL.

Research Products

• [Journal Article] CD25 as an adverse prognostic factor in elderly patients with acute myeloid leukemia. (2017)
  • Author(s): Fujiwara SI, Muroi K, Yamamoto C, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Ozawa K.
  • Journal Title: Hematology Volume: 18 Issue: 6 Pages: 1-7
  • DOI: 10.1080/10245332.2016.1276240
  • Peer Reviewed / Acknowledgement Compliant
• [Journal Article] Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma. (2017)
  • Author(s): Umino K, Fujiwara SI, Ito S, Mashima K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y.
  • Journal Title: Leuk Lymphoma. Volume: 58 Pages: 316-323
  • Peer Reviewed
• [Journal Article] Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP. (2017)
  • Author(s): Umino K, Fujiwara SI, Ikeda T, Toda Y, Ito S, Mashima K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y.
  • Journal Title: Hematology. Volume: 17 Issue: 9 Pages: 1-6
  • DOI: 10.1080/10245332.2017.1312204
  • Peer Reviewed
• [Journal Article] Development of acute myeloid leukemia in patients with untreated chronic lymphocytic leukemia. (2017)
  • Author(s): Ito S, Fujiwara SI, Mashima K, Umino K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Yamamoto C, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y.
  • Journal Title: Ann Hematol. Volume: 96 Issue: 5 Pages: 719-724
  • DOI: 10.1007/s00277-017-2933-x
  • Peer Reviewed
• [Journal Article] High-Dose Methotrexate and Cytarabine-Based Multi-Agent Chemotherapy (Modified Bonn Protocol) for Systemic Lymphoma with CNS Involvement. (2017)
  • Author(s): Umino K, Fujiwara SI, Sato K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Yamamoto C, Hatano K, Okazuka K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y.
  • Journal Title: Acta Haematol. Volume: 137 Issue: 2 Pages: 93-99
  • DOI: 10.1159/000454890
  • Peer Reviewed
• [Journal Article] The prognostic significance of rapid peripheral blood blast clearance during the initial course of induction chemotherapy in young patients with de novo acute myeloid leukemia. (2016)
  • Author(s): Nakano H, Fujiwara SI, Ito S, Mashima K, Umino K, Minakata D, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Yamamoto C, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y
  • Journal Title: Hematol Oncol. Volume: in press Issue: 3 Pages: 1-1
  • DOI: 10.1002/hon.2277
  • Peer Reviewed
• [Journal Article] A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis. (2016)
  • Author(s): Minakata D, Fujiwara SI, Ito S, Mashima K, Umino K, Nakano H, Kawasaki Y, Sugimoto M, Yamasaki R, Yamamoto C, Ashizawa M, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y
  • Journal Title: Leuk Res. Volume: 42 Pages: 82-87
  • DOI: 10.1016/j.leukres.2015.12.013
  • Peer Reviewed
• [Journal Article] Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia. (2016)
  • Author(s): Yamamoto C, Ito S, Mashima K, Umino K, Minakata D, Yamasaki R, Kawasaki Y, Sugimoto M, Nakano H, Ashizawa M, Okazuka K, Hatano K, Sato K, Oh I, Fujiwara S, Ohmine K, Suzuki T, Muroi K, Kanda Y.
  • Journal Title: Leuk Lymphoma. Volume: 25 Pages: 1-7
  • Peer Reviewed
• [Presentation] Soluble interleukin-2 receptor level after treatment predicts outcome of follicular lymphoma. (2016)
  • Author(s): 海野健斗、藤原慎一郎、伊藤祥子、真島清実、皆方大佑、中野裕史、山崎諒子、川崎泰史、杉本美幸、蘆澤正弘、畑野かおる、岡塚貴世志、山本千裕、佐藤一也、翁家国、大嶺謙、鈴木隆浩、室井一男、神田善伸
  • Organizer: 第78回日本血液学会学術集会
  • Place of Presentation: パシフィコ横浜（神奈川 横浜）
  • Year and Date: 2016-10-13
• [Presentation] CAG vs. DNR-AraC as induction therapy for elderly patients with AML A propensity score analysis (2015)
  • Author(s): Minakata Daisuke, Fujiwara Shin-ichiro, Umino Kento, Nakano Hirofumi, Kawasaki Yasufumi, Sugimoto Miyuki, Yamasaki Ryoko, Yamamoto Chihiro, Hatano Kaoru, Okazuka Kiyoshi, Sato Kazuya, Oh Iekuni, Ohmine Ken, Suzuki Takahiro, Nagai Tadashi, Muroi Kazuo, Kanda Yoshinobu.
  • Organizer: 第77回日本血液学会学術集会
  • Place of Presentation: 石川県立音楽堂他（金沢県石川市）
  • Year and Date: 2015-10-16
• [Presentation] Rapid decline in peripheral blood blast ratio predicts complete remission in patients with AML (2015)
  • Author(s): Nakano Hirofumi, Umino Kento, Minakata Daisuke, Yamasaki Ryoko, Kawasaki Yasufumi, Sugimoto Miyuki, Yamamoto Chihiro, Takizawa Haruko, Hatano Kaoru, Okazuka Kiyoshi, Sato Kazuya, Oh Iekuni, Fujiwara Shin-Ichiro, Ohmine Ken, Suzuki Takahiro, Nagai Tadashi, Muroi Kazuo, Kanda Yoshinobu.
  • Organizer: 第77回日本血液学会学術集会
  • Place of Presentation: 石川県立音楽堂他（金沢県石川市）
  • Year and Date: 2015-10-16
• [Presentation] Dose-reduced combination of MIT, ETP, and AraC(miniMEC) for relapsed and refractory acute leukemia (2015)
  • Author(s): Yamamoto Chihiro, Umino Kento, Minakata Daisuke, Yamasaki Ryoko, Kawasaki Yasufumi, Sugimoto Miyuki, Takizawa Haruko, Hatano Kaoru, Okazuka Kiyoshi, Sato Kazuya, Oh Iekuni, Fujiwara Shin-ichiro, Ohmine Ken, Suzuki Takahiro, Nagai Tadashi, Muroi Kazuo, Kanda Yoshinobu.
  • Organizer: 第77回日本血液学会学術集会
  • Place of Presentation: 石川県立音楽堂他（金沢県石川市）
  • Year and Date: 2015-10-16
• [Presentation] High-dose methotrexate-based multi-agent chemotherapy for systemic lymphoma with CNS involvement. (2015)
  • Author(s): Umino Kento, Fujiwara Shin-ichiro, Sato Kazuya, Minakata Daisuke, Nakano Hirofumi, Yamasaki Ryoko, Kawasaki Yasufumi, Sugimoto Miyuki, Yamamoto Chihiro, Takizawa Haruko, Hatano Kaoru, Okazuka Kiyoshi, Oh Iekuni, Ohmine Ken, Suzuki Takahiro, Nagai Tadashi, Muroi Kazuo, Kanda Yoshinobu.
  • Organizer: 第77回日本血液学会学術集会
  • Place of Presentation: 石川県立音楽堂他（金沢県石川市）
  • Year and Date: 2015-10-16
• [Presentation] 当院における輸血副作用報告の解析 (2015)
  • Author(s): 小幡 隆, 坂巻 佳織, 秋山 友子, 進藤 聖子, 大槻 郁子, 小林 美佳, 小野崎 文子, 中木 陽子, 菅野 直子, 岸野 光司, 藤原 慎一郎, 室井 一男
  • Organizer: 第63回 日本輸血・細胞治療学会 総会
  • Place of Presentation: 京王プラザホテル（東京都新宿区）
  • Year and Date: 2015-05-28